Literature DB >> 26052193

Palliative management of malignant upper urinary tract obstruction.

P Sountoulides1, I Mykoniatis1, N Dimasis2.   

Abstract

Malignancies of the genitourinary tract are diagnosed with increased frequency compared to the past. Currently prostate and bladder cancer account for the majority of urological malignancies. While for prostate cancer recent developments in the management of local and metastatic disease are likely to lead the majority of patients to either cure from the disease or to longer survival time, for bladder cancer advanced disease will unfortunately lead to death within months. However, the common clinical scenario in both prostate and bladder cancer includes, in high incidence, upper urinary tract obstruction in the advanced stages of these malignancies. This coupled with the fact that average life expectancy in the western world is increasing, will result in a significant patient population with either advanced, non-curable disease or with problems related to the received therapeutic surgical or medical interventions. There is no doubt that in both circumstances the room and role of palliation therapy is increasing. The care of patients with advanced urologic malignancies requires a multi-disciplinary effort from physicians of many specialties under the guiding role of the treating urologist. This review focuses on currently available palliative therapeutic options for upper urinary tract obstruction in the setting of patients with advanced malignancies of the urinary tract, as recently significant advancements have been witnessed in this field.

Entities:  

Keywords:  Urologic malignancies; nephrostomy; palliative management; upper urinary tract obstruction; ureteral stents

Year:  2014        PMID: 26052193      PMCID: PMC4453800     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  54 in total

1.  Quality improvement guidelines for percutaneous nephrostomy.

Authors:  Parvati Ramchandani; John F Cardella; Clement J Grassi; Anne C Roberts; David Sacks; Marc S Schwartzberg; Curtis A Lewis
Journal:  J Vasc Interv Radiol       Date:  2003-09       Impact factor: 3.464

2.  [Major urologic surgical procedures in locally advanced colorectal cancers].

Authors:  C Göktaş; R Horuz; M Yıldırım; G Faydacı; C Sahin; S Albayrak
Journal:  Actas Urol Esp       Date:  2012-01-21       Impact factor: 0.994

3.  The role of percutaneous nephrostomy in malignant ureteric obstruction.

Authors:  J R Wilson; G H Urwin; M J Stower
Journal:  Ann R Coll Surg Engl       Date:  2005-01       Impact factor: 1.891

Review 4.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

5.  Metallic ureteral stents in malignant ureteral obstruction: clinical factors predicting stent failure.

Authors:  Po-Ming Chow; Jui-Shan Hsu; Chao-Yuan Huang; Shuo-Meng Wang; Yuan-Ju Lee; Kuo-How Huang; Hong-Jheng Yu; Yeong-Shiau Pu; Po-Chin Liang
Journal:  J Endourol       Date:  2014-01-30       Impact factor: 2.942

Review 6.  Do's and don't's of percutaneous nephrostomy.

Authors:  R J Zagoria; R B Dyer
Journal:  Acad Radiol       Date:  1999-06       Impact factor: 3.173

Review 7.  Ureteral metal stents: 10-year experience with malignant ureteral obstruction treatment.

Authors:  Evangelos N Liatsikos; Dimitrios Karnabatidis; Konstantinos Katsanos; Panagiotis Kallidonis; Paraskevi Katsakiori; George C Kagadis; Nikolaos Christeas; Zafiria Papathanassiou; Petros Perimenis; Dimitrios Siablis
Journal:  J Urol       Date:  2009-12       Impact factor: 7.450

8.  Efficacy and safety of a novel, double-layered, coated, self-expandable metallic mesh stent (Uventa™) in malignant ureteral obstructions.

Authors:  Kyung Jin Chung; Bong Hee Park; Bumsoo Park; Jun Ho Lee; Woo Jung Kim; Minki Baek; Deok Hyun Han
Journal:  J Endourol       Date:  2013-06-12       Impact factor: 2.942

9.  New ePTFE/FEP-covered stent in the palliative treatment of malignant biliary obstruction.

Authors:  Mario Bezzi; Aleksejs Zolovkins; Vito Cantisani; Filippo Maria Salvatori; Michele Rossi; Fabrizio Fanelli; Plinio Rossi
Journal:  J Vasc Interv Radiol       Date:  2002-06       Impact factor: 3.464

Review 10.  Drug-eluting metallic stents in urology.

Authors:  Panagiotis S Kallidonis; Ioannis S Georgiopoulos; Iason D Kyriazis; Abdulrahman M Al-Aown; Evangelos N Liatsikos
Journal:  Indian J Urol       Date:  2014-01
View more
  2 in total

1.  Ureteral obstruction by prostate cancer leads to spontaneous ureteric rupture: a case report.

Authors:  Fei Deng; Xuemei Liu; Yixiao Li; Yihong Zhou; Jin Tang; Yuxin Tang; Yingbo Dai
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  The profile of patients with obstructive uropathy in Cameroon: case of the Douala General Hospital.

Authors:  Marie Patrice Halle; Linda Njonkam Toukep; Samuel Ekane Nzuobontane; Hermine Fouda Ebana; Gregory Halle Ekane; Eugene Belley Priso
Journal:  Pan Afr Med J       Date:  2016-03-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.